EyePoint Pharmaceuticals Inc at Guggenheim Healthy Altitudes Summit Transcript
Good morning, everyone. My name is Yatin Suneja, and one of the biotech analyst here at Guggenheim. Thank you, everybody, for joining us this morning on day two of our Guggenheim Healthy Altitude Summit. Our first presenting company of today is EyePoint. And from the company, we have Chief Executive Officer, Nancy Lurker. We also have the Chief Financial Officer, George Elston.
Nancy, why don't you take maybe one to two minutes, give an intro to the story and then we'll go into the Q&A.
Yeah. So EyePoint Pharmaceuticals, we've got our lead asset. It's in a Phase 2 for wet AMD. It's a potential six-month bioerodible insert injected in the doctor's office intravitreally to be able to get patients at six months. So that, we're in two Phase 2 trials, wet AMD, diabetic retinopathy. Both trials are enrolling very, very nicely. And we expect to have readout on our Phase 2 data in December of this year.
That study will be 150 patients, and it is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |